IO Biotech, Inc. IOBT 深 沪
等待开盘 08-15 09:30:00 美东时间
1.28
-0.030
-2.29%
华盛通- 最 高1.41
- 今 开1.33
- 成交量 331.32万股
- 最 低 1.23
- 昨 收 1.31
- 总市值 8432.76万
- 52周最高 2.4773
- 市盈率 静 --
- 换手率 5.03%
- 52周最低 0.66
- 委 比 96.53%
- 总股本 6588.09万
- 历史最高 17.88
- 量 比 0.16
- 振 幅 13.74%
- 历史最低 0.66
- 每 手 1
- 风险率 0.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多IO Biotech Q2 EPS $(0.40) Misses $(0.35) Estimate
IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.35) by 13.64 percent. This is a 29.03 percent decrease over losses of $(0.31) per share from the
今天 04:35
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers IO Biotech (NASDAQ:IOBT) stock rose 52.5% to $2.76 during Monday's pre...
08-11 20:08
Market-Moving News for August 11th
MNDY: -19% | Monday.Com Q2 Adj. EPS $1.09 Beats $0.86 Estimate, Sales $299.01M Beat $293.54M Estimate IOBT: 66% | Reported Sunday, IO Biotech To Reveal Topline Phase 3 Results For Cylembio Plus KEYTRUDA In
08-11 19:25
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
IO Biotech announced topline results from a pivotal Phase 3 trial of its investigational cancer vaccine Cylembio in combination with pembrolizumab for the treatment of advanced melanoma. The trial showed an improvement in progression-free survival (PFS) for patients treated with Cylembio plus pembrolizumab compared to pembrolizumab alone (median PFS 19.4 months vs. 11.0 months), though statistical significance on the primary endpoint was narrowly...
08-11 12:00
IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
IO Biotech will hold a conference call on August 11, 2025, to discuss Phase 3 trial results of its cancer vaccine, Cylembio, in treating advanced melanoma. The company, developing immune-modulatory vaccines, has seen its candidate granted Breakthrough Therapy Designation by the FDA. The call will provide insight into the pivotal trial comparing Cylembio with pembrolizumab alone.
08-10 12:00
IO Biotech Elects New Director at Annual Meeting
The latest update is out from IO Biotech ( ($IOBT) ). On June 5, 2025, IO Biote...
06-10 05:17
IO Biotech Files For For Resale Of Up To 5,623,664 Shares By Selling Stockholders
-SEC Filing
05-24 04:09
IO Biotech Q1 EPS $(0.34) Beats $(0.38) Estimate
IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.38) by 10.53 percent. This is a 13.33 percent decrease over losses of $(0.30) per share from the
05-14 20:15
美股大行评级 | 富国银行：维持艾伯维"超配"评级，目标价从210美元升至240美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1104327819967434752.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Syndax制药(SNDX)"超配"评级，目标价从35美元升至39美元</p> <p>• 摩根大通：维持AnaptysBio(ANAB)"超配"评级，目标价从36美元升至42美元</p> <p>• 摩根大通
03-06 11:20
IO Biotech Secures €57.5 Million EIB Loan Facility
The latest announcement is out from IO Biotech ( ($IOBT) ). IO Biotech has secu...
2024-12-20 21:27
